ArticleInfluenza and other respiratory viruses2013
The dynamics of infection and the persistence of immunity to A(H1N1)pdm09 virus in Israel.
Article in Influenza and other respiratory viruses, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 12 citations in OpenAlex.
- Article
- Characterizing the transmission patterns of seasonal influenza in Italy: lessons from the last decade.BMC public health · 2022Article
- Inferring high-resolution human mixing patterns for disease modeling.Nature communications · 2021Article
- Reactive school closure weakens the network of social interactions and reduces the spread of influenza.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Model-based reconstruction of an epidemic using multiple datasets: understanding influenza A/H1N1 pandemic dynamics in Israel.Journal of the Royal Society, Interface · 2016Article
- Ineffectiveness of the 2014-2015 H3N2 influenza vaccine.Oncotarget · 2016Article
- Article
- Seasonal Influenza A H1N1pdm09 Virus and Severe Outcomes: A Reason for Broader Vaccination in Non-Elderly, At-Risk People.PloS one · 2016Observational
- Return of pandemic H1N1 influenza virus.BMC infectious diseases · 2014Article
- Relationships between A(H1N1)pdm09 influenza infection and infections with other respiratory viruses.Influenza and other respiratory viruses · 2014Article
- The dynamics of infection and the persistence of immunity to A(H1N1)pdm09 virus in Israel.Influenza and other respiratory viruses · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInfluenza virus A(H1N1)pdm09 first appeared in Israel in late April 2009, disappeared in mid-March 2010, and reappeared in late October 2010. Symptoms were mostly mild without need for medical care.
objectivesTo provide targets for future pandemic preparedness and response by evaluating the dynamics and cumulative incidence of A(H1N1)pdm09 infection, the virus-specific seroprevalence (HI antibody titer >1:40) at the height of the pandemic, during its decline and thereafter.
methodsA cross-sectional seroepidemiological study was conducted on 6911 serum samples collected before, during, and after the pandemic.
resultsCumulative incidence of infection derived from the differences between post- and pre-pandemic seroprevalence was 54.1%, 32.9%, 22.9%, 14.8%, and 6.3% in age-groups 0-9, 10-19, 20-49, 50-79, and ≥ 80 years, respectively, and 28.5% for all age-groups combined. Vaccination could have contributed at the most 4.6% to the post-pandemic population seroprevalence. High pre-pandemic immune response (47.4%) found in a cohort aged 15-18 year was strongly associated with birth years 1990-1993. Morbidity began to decline in mid-November 2009 at 32.8% population seroprevalence (45% in ages 0-19 year) and stopped in March 2010 at 43.4% population seroprevalence in February 2010 (70% in ages 0-19 year). Between February and September 2010, seroprevalence declined by 12.2% allowing virus recirculation from October 2010.
conclusionsOur study provides targets for controlling future influenza pandemics in Israel. Vaccination should focus on the younger age-groups (0-19 year) which played a key role in transmission of the A(H1N1)pdm09 due to lack of background immunity (ages 0-9 year) and high exposure rates (ages 10-19 year).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.